Prior studies have shown the involvement of TRPV1 in rodent models of primary bone cancer pain, and TRPV1 antagonists significantly attenuated primary bone cancer-related pain behaviors (Ghilardi et al., 2005; Shinoda et al., 2008; Pan et al., 2010). Here, TRPV1 is linked to bone neoplasm.